A phase II study for the safety and efficacy of TAS-102 and Bevacizumab for patients with unresectable colorectal cancer considering Oxaliplatin to stop and go.
Active, not recruitingJPRN-UMIN000022535
Gunma Universityunresectable colorectal cancer
Start: 2015-05-30Target: 45Updated: 2026-06-29